We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

VX-950 and Peginterferon for Hepatitis C

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00251199
First Posted: November 9, 2005
Last Update Posted: December 21, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Vertex Pharmaceuticals Incorporated
  Purpose
VX-950 is an investigational drug , which is being tested in combination with a known treatment for hepatitis C, peginterferon.

Condition Intervention Phase
Hepatitis C Drug: VX-950 Drug: peginterferon Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Official Title: A Phase 1b Viral Kinetic Study of VX-950 and Peginterferon in Hepatitis C

Resource links provided by NLM:


Further study details as provided by Vertex Pharmaceuticals Incorporated:

Primary Outcome Measures:
  • Viral kinetics

Secondary Outcome Measures:
  • Assess the safety of VX-950 in combination with peginterferon

Estimated Enrollment: 20
Study Start Date: October 2005
Study Completion Date: March 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • infected with Hepatitis C virus

Exclusion Criteria:

  • contraindications to peginterferon therapy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00251199


Locations
Germany
Call for information
Homburg/Saar, Germany
Netherlands
Call for information
Amsterdam, Netherlands
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
Investigators
Study Director: Medical Monitor Vertex Pharmaceuticals Incorporated
  More Information

ClinicalTrials.gov Identifier: NCT00251199     History of Changes
Other Study ID Numbers: VX05-950-103
First Submitted: November 7, 2005
First Posted: November 9, 2005
Last Update Posted: December 21, 2007
Last Verified: December 2007

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections